Printer Friendly

Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009.

WATERTOWN, Mass., Sept. 10 /PRNewswire/ -- Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090910/NE72856LOGO )

"We appreciate the opportunity to share some of the results from our work with this very powerful and ground-breaking chemistry platform," stated Mr. Guy Macdonald, President and CEO of Tetraphase Pharmaceuticals. "This enabling chemistry technology dramatically expands the chemical diversity of tetracyclines and is highly versatile, providing compounds with possibilities for IV and oral dosing routes and activity against multiple drug-resistant strains."

The oral presentation will be given in Hall B at the Moscone Center, in the session entitled "New Protein Synthesis Inhibitors: Oxazolidinones, Pleuromutilins and Tetracyclines", as follows:
 September 14th (9:00 a.m. - 9:15 a.m., Poster Session 142)

 -- Presentation Number F1-1219 - Oral Antibacterial Activity of a Novel
 Pentacycline




The posters will be presented in Hall B at the Moscone Center, in the session entitled "New Protein Synthesis Inhibitors: Oxazolidinones, Pleuromutilins and Tetracyclines" as follows:
 September 14th (11:15 a.m. - 1:15 p.m., Poster Session 166)

 -- Presentation Number F1-1514: Synthesis and Antibacterial Activities
 of Aza Tetracyclines: A Novel Class of Tetracycline Analogs


 -- Presentation Number F1-1515: In Vitro and In Vivo Activities of Novel
 Broad-Spectrum 8-Aza Tetracyclines


 -- Presentation Number F1-1516: Synthesis and Antibacterial Activities
 of Pentacyclines: A Novel Class of Tetracycline Analogs




Copies of the oral presentation and the posters will be available at ICAAC and on the Tetraphase website (http://www.tphase.com/) following ICAAC.

About Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals is capitalizing on breakthrough synthetic chemistry technology for drug discovery and development based on a process developed by world-leading organic chemist Dr. Andrew Myers of Harvard University. This enabling advance in chemistry provides the company with a broad range of commercial opportunities across a number of significant disease categories.

CONTACT: Leland Webster, Ph.D., Tetraphase Pharmaceuticals, Inc., +1-617-715-3587, lwebster@tphase.com

Web Site: http://www.tphase.com/
COPYRIGHT 2009 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 10, 2009
Words:366
Previous Article:Atna Reports Significant Gold Resource for its Columbia Gold Project.
Next Article:Do As I Say Not As I Do: New Liberty Mutual Survey Reveals That Parents Set Poor Driving Examples for Their Teen Drivers.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters